Calcium Pyrophosphate Crystal Deposition: Insights to Risks Factors and Associated Conditions.

CPPD Calcium Pyrophosphate Deposition Disease Comorbidities Pseudogout Risk Factors

Journal

Current rheumatology reports

ISSN: 1534-6307

Titre abrégé: Curr Rheumatol Rep

Pays: United States

ID NLM: 100888970

Informations de publication

Date de publication:
05 Aug 2024

Historique:

accepted: 10 07 2024

medline: 5 8 2024

pubmed: 5 8 2024

entrez: 5 8 2024

Statut: aheadofprint

Résumé

This review provides an overview of medical conditions and risk factors associated with CPPD. Recent studies have indicated that CPPD patients may have a higher risk for systemic conditions such as cardiovascular diseases. Calcium pyrophosphate deposition disease (CPPD) is a common crystal arthropathy that primarily affects older adults, and, in most cases, the aetiology is idiopathic. Age is the most remarkable risk factor and due to the aging population, the prevalence of this condition is expected to increase. Strong evidence supports an association between CPPD and several metabolic and endocrine conditions, including hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypophosphatasia. Additionally, there is growing evidence of an increased risk for cardiovascular diseases among CPPD patients, alongside potential links to rheumatic disorders, gender, medications, and joint trauma. Further research is needed to explore the underlying mechanisms linking CPPD to associated conditions and to develop targeted therapies with the aim of improving patient outcomes.

Identifiants

DOI: 10.1007/s11926-024-01158-5 PMID: 39101956

pubmed: 39101956

doi: 10.1007/s11926-024-01158-5

pii: 10.1007/s11926-024-01158-5

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Rosenthal AK, Lawrence RA. Calcium Pyrophosphate Deposition Disease. N Engl J Med.2016;374:2575–84. This review comprehensively covers all pertinent information regarding CPPD disease, including the key risk factors and associated condition. https://doi.org/10.1056/NEJMra1511117 .

Abhishek A. Calcium pyrophosphate deposition disease. Curr Opin Rheumatol. 2016;28:133–9. https://doi.org/10.1097/BOR.0000000000000246 .

doi: 10.1097/BOR.0000000000000246 pubmed: 26626724

Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population. Rheumatology (Oxford). 2012;51:2070–4. https://doi.org/10.1093/rheumatology/kes204 .

doi: 10.1093/rheumatology/kes204 pubmed: 22886340

Ryu K, Iriuchishima T, Oshida M, Kato Y, Saito A, Imada M, Aizawa S, Tokuhashi Y, Ryu J. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint. Osteoarthritis Cartilage. 2014;22(7):975–9. https://doi.org/10.1016/j.joca.2014.04.022 .

doi: 10.1016/j.joca.2014.04.022 pubmed: 24814686

Ramonda R, Musacchio E, Perissinotto E, Sartori L, Punzi L, Corti MC, Hirsch R, Manzato E, Zambon S, Baggio G, Crepaldi G. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27:981–4.

pubmed: 20149316

Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Association between low cortical bone mineral density, soft-tissue calcification, vascular calcification and chondrocalcinosis: a case-control study. Ann Rheum Dis. 2013;73:1997–2002. https://doi.org/10.1002/acr.21952 .

doi: 10.1002/acr.21952 pubmed: 23912799

Abhishek A, Doherty S, Maciewicz RA, Muir KR, Zhang W, Doherty M. Self-reported knee malalignment in early adult life as an independent risk for knee chondrocalcinosis. Arthritis Care Res (Hoboken). 2011;63:1550–7. https://doi.org/10.1002/acr.20593 .

doi: 10.1002/acr.20593 pubmed: 22034117

Doherty M, Watt I, Dieppe P. Localised chondrocalcinosis in post-meniscectomy knees. Lancet. 1982;319:1207–10. https://doi.org/10.1016/s0140-6736(82)92336-4 .

doi: 10.1016/s0140-6736(82)92336-4

Roddy E, Muller S, Paskins Z, Hider S, Blagojevic-Bucknall M, Mallen C. Incident acute pseudogout and prior bisphosphonate use. Medicine. 2017;96:e6177. https://doi.org/10.1097/MD.0000000000006177 .

doi: 10.1097/MD.0000000000006177 pubmed: 28328803 pmcid: 5371440

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20. https://doi.org/10.1016/j.amjmed.2012.06.023 .

doi: 10.1016/j.amjmed.2012.06.023 pubmed: 23177553

Felson DT, Rabasa G, Chen X, LaValley M, Jafarzadeh SR, Lewis CE, Torner J, Nevitt MC, Misra D, MOST Study Investigators. The Association of Diuretics and Proton Pump Inhibitors With Chondrocalcinosis. ACR Open Rheumatol. 2021;3:390–4. https://doi.org/10.1002/acr2.11260 .

doi: 10.1002/acr2.11260 pmcid: 8207690

Liew JW, Peloquin C, Tedeschi SK, Felson DT, Zhang Y, Choi HK, Terkeltaub R, Neogi T. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study. Arthritis Care Res (Hoboken). 2022. https://doi.org/10.1002/acr.24876 .

doi: 10.1002/acr.24876 pubmed: 36239292

Jones AC, Chuck AJ, Arie EA, Green DJ, Doherty M. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 1992;22:188–202. This article delves into the diseases associated with CPPD, exploring their potential pathophysiologic correlations. https://doi.org/10.1016/0049-0172(92)90019-a .

Kleiber Balderrama C, Rosenthal A, Lans D, Singh J, Bartels C. Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans. Arthritis Care Res. 2017;69:1400–6. https://doi.org/10.1002/acr.23160 .

doi: 10.1002/acr.23160

Bashir M, Sherman KA, Solomon DH, Rosenthal A, Tedeschi SK. Cardiovascular disease risk in calcium pyrophosphate deposition disease: A nationwide study of veterans. Arthritis Care Res (Hoboken). 2021. https://doi.org/10.1002/acr.24783 . This is the first study to demonstrate an association between CPPD and cardiovascular disease.

Tedeschi S, Huang W, Yoshida, Solomon D. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. Annals of the Rheumatic Diseases.2022;81:1323–1329. The first study to reveal a link among acute CPPD arthritis and cardiovascular events. https://doi.org/10.1136/annrheumdis-2022-222387 .

Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900. https://doi.org/10.1161/CIRCULATIONAHA.107.703389 .

doi: 10.1161/CIRCULATIONAHA.107.703389 pubmed: 17698728

Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45–52. https://doi.org/10.1093/rheumatology/kes243 .

doi: 10.1093/rheumatology/kes243 pubmed: 22986289

Calò L, Punzi L, Semplicini A. Hypomagnesemia and chondrocalcinosis in Bartter’s and Gitelman’s syndrome: review of the pathogenetic mechanisms. Am J Nephrol. 2000;20:347–50. https://doi.org/10.1159/000013614 .

doi: 10.1159/000013614 pubmed: 11092989

Al Shibli A, Narchi H. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J Methodol. 2015;5:55–61. https://doi.org/10.5662/wjm.v5.i2.55 .

doi: 10.5662/wjm.v5.i2.55 pubmed: 26140272 pmcid: 4482822

Hisakawa N, Yasuoka N, Itoh H, Takao T, Jinnouchi C, Nishiya K, Hashimoto K. A Case of Gitelman’s Syndrome with Chondrocalcinosis. Endocr J. 1998;4:261–7. https://doi.org/10.1507/endocrj.45.261 .

doi: 10.1507/endocrj.45.261

Oliviero F, Scanu A, Punzi L. Metabolism of crystals within the joint. Reumatismo. 2011;63:221–9. https://doi.org/10.4081/reumatismo.2011.221 .

doi: 10.4081/reumatismo.2011.221

Volpe A, Guerriero A, Marchetta A, Caramaschi P, Furlani L. Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. Joint Bone Spine. 2009;76:708–10. https://doi.org/10.1016/j.jbspin.2009.02.001 .

doi: 10.1016/j.jbspin.2009.02.001 pubmed: 19467900

Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW Jr, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore). 1981;60:397–412. https://doi.org/10.1097/00005792-198111000-00002 .

doi: 10.1097/00005792-198111000-00002 pubmed: 7311809

Alix L, Guggenbuhl P. Familial hypocalciuric hypercalcemia associated with crystal deposition disease. Joint Bone Spine. 2015;82:60–2. https://doi.org/10.1016/j.jbspin.2014.08.007 .

doi: 10.1016/j.jbspin.2014.08.007 pubmed: 25444087

Husar-Memmer E, Stadlmayr A, Datz C, Zwerina J. HFE-related hemochromatosis: an update for the rheumatologist. Curr Rheumatol Rep. 2014;16:393. https://doi.org/10.1007/s11926-013-0393-4 .

doi: 10.1007/s11926-013-0393-4 pubmed: 24264720

Eade AW, Swannell AJ, Williamson N. Pyrophosphate arthropathy in hypophosphatasia. Ann Rheum Dis. 1981;40:164–70. https://doi.org/10.1136/ard.40.2.164 .

doi: 10.1136/ard.40.2.164 pubmed: 6261701 pmcid: 1000700

O’Duffy JD. Hypophosphatasia associated with calcium pyrophosphate dihydrate deposits in cartilage. Arthritis Rheum. 1970;13:381–8. https://doi.org/10.1002/art.1780130404 .

doi: 10.1002/art.1780130404 pubmed: 4317094

Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366:904–13. https://doi.org/10.1056/NEJMoa1106173 .

doi: 10.1056/NEJMoa1106173 pubmed: 22397652

Centers for Disease Control and Prevention. Osteoarthritis (OA). Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/arthritis/basics/osteoarthritis.htm . Accessed 13 Nov 2022.

Jaccard YB, Gerster JC, Calame L. Mixed monosodium urate and calcium pyrophosphate crystal-induced arthropathy. A review of seventeen cases. Rev Rhum Engl Ed. 1996;63:331–5.

pubmed: 8789878

Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022;8:e002383. https://doi.org/10.1136/rmdopen-2022-002383 .

doi: 10.1136/rmdopen-2022-002383 pubmed: 35701012 pmcid: 9198698

Sabchyshyn V, Konon I, Ryan LM, Rosenthal AK. Concurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A case collection and review of the literature. Semin Arthritis Rheum. 2018;48:9–11. https://doi.org/10.1016/j.semarthrit.2017.11.009 .

doi: 10.1016/j.semarthrit.2017.11.009 pubmed: 29338885

Gerster JC, Varisco PA, Kern J, Dudler J, So AK. CPPD crystal deposition disease in patients with rheumatoid arthritis. Clin Rheumatol. 2006;25:468–9. https://doi.org/10.1007/s10067-005-0082-4 .

doi: 10.1007/s10067-005-0082-4 pubmed: 16365684